Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy is the brand name Novo Nordisk gave to its semaglutide injection when it was licensed specifically for weight management. The name is a registered trademark, not a clinical term, and it distinguishes this formulation from Ozempic, which contains the same active ingredient but is licensed only for type 2 diabetes. Wegovy is a prescription-only medicine in the UK, and a prescriber decides whether it is clinically suitable for each person.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Brand names in medicine tend to be invented words chosen for trademark reasons rather than any medical meaning. Wegovy follows that pattern exactly. Novo Nordisk coined it to create a distinct identity for semaglutide when used for weight management, separating it commercially and regulatorily from their earlier semaglutide products. The word itself carries no pharmacological clue, you learn nothing about the drug from the syllables alone.
The active substance, semaglutide, is where the meaning sits. Semaglutide is a GLP-1 receptor agonist: it mimics a hormone released naturally after eating, slowing the stomach's emptying rate and signalling fullness to the brain. That dual action (gut and brain) is why appetite falls on treatment. If you want to understand what Wegovy actually does inside the body, the ingredient breakdown for Wegovy covers the formulation in detail.
One thing the name does signal, indirectly, is that this is not a generic. Wegovy is a branded, patented medicine. Any product sold online using the Wegovy name without coming through a GPhC-registered UK pharmacy should be treated as suspect, the MHRA Yellow Card service exists partly to receive reports of suspect sellers.
This is the question that trips most people up. Three licensed semaglutide products exist in the UK, and knowing which is which matters before you speak to any prescriber.
Ozempic is a once-weekly injection for type 2 diabetes. Rybelsus is a once-daily tablet, also for type 2 diabetes. Neither is licensed for weight management. Wegovy (both the injection and the tablet) is the formulation licensed for weight loss in adults. The doses are different, the indications are different, and the legal routes to each are different. A prescriber writing a Wegovy prescription is doing something categorically distinct from one writing Ozempic, even though the molecule is the same. The semaglutide overview on this site sets out all three products side by side.
Confusing them matters practically, not just academically. People sometimes seek Ozempic for weight loss because it became more widely known first. Supplying it for that purpose is off-label, and no reputable UK prescriber will do so when Wegovy exists and is licensed for exactly that purpose.
Wegovy's history in the UK has moved quickly. The injection was the original product. It starts at 0.25 mg and is titrated every four weeks by the prescriber, with 2.4 mg as the standard maintenance dose. The MHRA then approved a higher 7.2 mg dose in January 2026 and, on 14 April 2026, cleared a dedicated single-dose 7.2 mg pen, one pre-set injection per week, with a built-in covered needle that locks after use. If you want to understand the full range of strengths available, including how high the Wegovy dose can go, the guide to what doses Wegovy comes in covers each step of the titration schedule in detail.
Then, on 11 June 2026, the MHRA approved the Wegovy tablet, oral semaglutide co-formulated with an absorption enhancer called SNAC. The UK was the first country in Europe to clear it for weight management. It requires no fridge, making it more straightforward to store and travel with. The titration schedule runs from 1.5 mg daily through 4 mg and 9 mg to a 25 mg maintenance dose. In the OASIS 4 trial, participants lost an average of around 13.6% of their body weight over 64 weeks; among those who adhered fully throughout, the average was roughly 17%. The full Wegovy guide covers both formats.
Which format suits any individual is a clinical call, not a consumer choice. A prescriber weighs injection tolerance, routine, existing medicines, and a range of health factors. That conversation is where the decision actually happens.
People searching what Wegovy means often move quickly to what it costs. That is a reasonable sequence. Private treatment prices vary by dose, provider and which format you use. Eli Lilly's price increase in September 2025 pushed Mounjaro list prices significantly upward; Wegovy private pricing has followed a similar market dynamic. For a grounded look at how UK private prices break down, the Wegovy price comparison guide works through what the numbers typically include, and what they often leave out.
A plain fact worth having early: any legitimate UK price for Wegovy includes a prescription, which means it includes a clinical assessment. A quote that does not mention a prescriber or a consultation is a red flag, not a bargain. The medicine is prescription-only under UK law, and that has practical implications for where it can legally come from.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.